Table 1 Characteristics of reports associated with durvalumab from Q1 2004 to Q1 2024
Indicators | Number of patients (%) |
|---|---|
Overall number of patients | 9447 |
Gender | |
 Female | 2620 (27.73) |
 Male | 5379 (56.94) |
 Not Specified | 1448 (15.33) |
Age (years) | |
 < 18 | 4 (0.04) |
 18–44 | 190 (2.01) |
 45–64 | 2296 (24.30) |
 65–74 | 2525 (26.73) |
 ≥ 75 | 1346 (14.25) |
 Not Specified | 3086 (32.67) |
 Mean (SD) | 66.25 (10.38) |
 Median (Q1, Q3) | 67.83 (60.00, 73.07) |
 Min, Max | 0.00, 100.00 |
Reported person | |
 Consumer | 1550 (16.41) |
 Pharmacist | 1091 (11.55) |
 Physician | 5707 (60.41) |
 Other health-professional | 142 (1.50) |
 Not Specified | 957 (10.13) |
Reported countries | Â |
 Japan | 2559 (27.09) |
 United States of America | 2115 (22.39) |
 China | 1113 (11.78) |
 Canada | 650 (6.88) |
 France | 562 (5.95) |
Serious report | Â |
 Serious | 8821 (93.37) |
 Non-Serious | 626 (6.63) |
Outcome | Â |
 Life-Threatening | 790 (8.36) |
 Hospitalization-Initial or Prolonged | 3234 (34.23) |
 Disability | 193 (2.04) |
 Death | 2870 (30.38) |
 Congenital Anomaly | 5 (0.05) |
 Intervention | 11 (0.12) |
 Other | 4503 (47.67) |
Onset time (days) | |
 0–30 | 1552 (16.43) |
 31–60 | 664 (7.03) |
 61–90 | 391 (4.14) |
 91–120 | 266 (2.82) |
 121–150 | 165 (1.75) |
 151–180 | 104 (1.10) |
 181–360 | 324 (3.43) |
 > 360 | 121 (1.28) |
 Not Specified | 5860 (62.03) |
 Mean (SD) | 83.74 (136.60) |
 Median (Q1, Q3) | 41.00 (14.00,99.00) |
 Min, Max | 0.00, 3657.00 |
Reporting year | |
 2014 | 2 (0.02) |
 2015 | 1 (0.01) |
 2016 | 3 (0.03) |
 2017 | 178 (1.88) |
 2018 | 621 (6.57) |
 2019 | 1037 (10.98) |
 2020 | 1880 (19.90) |
 2021 | 1323 (14.00) |
 2022 | 1290 (13.66) |
 2023 | 2239 (23.70) |
 2024 | 873 (9.24) |